Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Telaprevir, a new treatment for hepatitis C by Vertex Pharmaceuticals, is showing positive results from a late-stage study, boosting company shares. But TheStreet.com warns that despite the promising results, the treatment has issues that may be making investors cautious, including a link to the serious allergic reaction Stevens Johnson Syndrome (SJS).

Read the rest of this entry »

PEGASYS, a new medication proven effective in the treatment of hepatitis C for Latino patients caused a severe adverse skin reaction known as erythema multiforme major, or Stevens Johnson Syndrome (SJS), in patients during post-approval use, according to Cloud Computing Journal. The article referenced a study published in the New England Journal of Medicine.

Read the rest of this entry »